| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $9,058,242 ) |
| | 2025 | 2025 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | AY2AX000034 | The Development of a Novel Molecular Platform, Non-Invasive Sonodynamic Therapeutic Devices, for the treatment of Hematologic Malignancies | 000 | 1 | NIH | 12/11/2024 | $9,115,161 |
| | 2025 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA261516 | Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | 000 | 2 | NIH | 1/31/2025 | -$56,919 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2024 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 003 | 2 | FDA | 9/4/2024 | $0 |
| | 2024 | 2024 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 002 | 2 | FDA | 8/21/2024 | -$488,084 |
| | 2024 | 2024 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 001 | 2 | FDA | 7/24/2024 | -$1 |
| | 2024 | 2024 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 000 | 2 | FDA | 7/23/2024 | $488,085 |
| | 2024 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA275508 | Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | 001 | 1 | NIH | 8/8/2024 | $0 |
| | 2024 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA261516 | Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | 000 | 2 | NIH | 8/12/2024 | $0 |
| | 2024 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA275508 | Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | 000 | 1 | NIH | 6/21/2024 | $0 |
| | 2024 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA275508 | Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | 002 | 1 | NIH | 9/26/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,755,859 ) |
| | 2023 | 2023 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA261516 | Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | 000 | 2 | NIH | 4/12/2023 | $1,061,045 |
| | 2023 | 2023 | SONALASENSE INC | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R44CA275508 | Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | 000 | 1 | NIH | 3/21/2023 | $694,814 |
| | 2023 | 2022 | SONALASENSE, INC. | 1111 BROADWAY | OAKLAND | CA | 94607-4036 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 000 | 1 | FDA | 7/19/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,415,961 ) |
| | 2022 | 2022 | SONALASENSE INC | 2600 10TH ST STE 435 | BERKELEY | CA | 94710-3105 | ALAMEDA | USA | R01FD007538 | Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma | 000 | 1 | FDA | 9/22/2022 | $477,006 |
| | 2022 | 2022 | SONALASENSE INC | 2600 10TH ST STE 435 | BERKELEY | CA | 94710-3105 | ALAMEDA | USA | R44CA261516 | Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | 000 | 1 | NIH | 4/15/2022 | $938,955 |
|
|
